RNA-based medicines have had a checkered development history, including a mixed bag of results last year at some of the leading players such as Alnylam Pharmaceuticals Inc. and Moderna Therapeutics LLC. Following its false start with siRNA, Seattle-based PhaseRx Inc., which raised $18.5m in a May 2016 IPO (and has raised about $70m since its formation in 2006), is focusing on mRNA and has developed a technology that combines a lipid nanoparticle (LNP) carrier with a proprietary polymer.
PhaseRx Makes More Noise Than Silence With mRNA Delivery
Having ditched silence RNA in 2012, PhaseRx president and CEO Dr Robert Overell explains to Mike Ward, global director of content at Informa Pharma Intelligence’s insights portfolio, how delivering messenger RNA inside diseased cells may revolutionize and grow the current $4bn enzyme replacement market.
More from R&D
More from Scrip
• By
CEO Paul Stoffels exits early to be succeeded by Henry Gosebruch, who will now consider ‘all options’ for the Belgian firm as it tries to claw back investor confidence.
• By
As CEO Anderson backs high prices for innovative drugs in Europe
• By
Novo Nordisk enjoyed a surprise GLP-1 agonist contracting win in the first quarter of 2025. This provided a welcome boost to its stock after it had spent the previous quarter on the back foot against rival Lilly.